false 0001335105 0001335105 2024-05-24 2024-05-24 0001335105 LIXT:CommonStockParValue0.0001PerShareMember 2024-05-24 2024-05-24 0001335105 LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember 2024-05-24 2024-05-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 24, 2024

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

delaware 001-39717 20-2903526
(State or other jurisdiction
of incorporation)
(Commission
File Number)

(I.R.S. Employer
Identification Number)

 

680 East Colorado Boulevard, Suite 180

Pasadena California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share  

LIXT

 

The NASDAQ Stock Market, LLC

Warrants to Purchase Common Stock, par value $0.0001 per share  

LIXTW

 

The NASDAQ Stock Market, LLC

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company’s Chief Medical Officer. Accordingly, such employment agreement will expire on July 31, 2024.

 

The Company intends to appoint a new Chief Medical Officer effective August 1, 2024.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 29, 2024

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

                         (Registrant)

     
  By: /s/ BASTIAAN VAN DER BAAN
    Bastiaan van der Baan
    Chief Executive Officer